Background. Coccidioidomycosis is a fungal infection of the desert southwestern United States. It may be selflimited or may require antifungal therapy. Currently used triazoles (eg, fluconazole and itraconazole) have largely supplanted amphotericin B, which is fraught with adverse effects. Limited case reports and small open-label trials show that voriconazole and posaconazole benefit patients with coccidioidomycosis refractory to first-line agents.
Coccidioidomycosis is a fungal infection caused by the soil-dwelling Coccidioides species, which are endemic to regions of the southwestern United States, northern Mexico, and Central and South America [1] . In most infected persons, coccidioidomycosis is either asymptomatic or self-limited [2] . Severe or protracted infections can occur in otherwise healthy persons but are more likely in those with underlying immunosuppressive illnesses [1, 2] .
For most coccidioidal infections requiring antifungal treatment, fluconazole has emerged as the agent of choice, largely supplanting its effective but toxic predecessor, amphotericin B [3] . Itraconazole is also an effective oral agent, but its use is limited by drug interactions and poor bioavailability in the absence of gastric acid. Rarely, patients with coccidioidomycosis require an alternate antifungal treatment because of refractory infection or medication intolerance.
Voriconazole [4] [5] [6] [7] and posaconazole [8] [9] [10] are newer triazole antifungal agents with demonstrated benefit in patients intolerant of other antifungal treatments or whose coccidioidal infection is refractory to other antifungal treatments. However, experience with these agents is limited to case reports or small case series. Posaconazole was found to be effective primary therapy in a small open-label trial of patients with pulmonary and nonmeningeal disseminated coccidioidal infection [11] . In this report, we summarize a single institution's use of voriconazole and posaconazole as salvage treatment for patients intolerant of other antifungal agents or with coccidioidomycosis refractory to other antifungals.
METHODS
Our tertiary care referral center is located in Maricopa County, Arizona, an area of high Coccidioides endemicity with .200 cases per 100 000 population reported in 2009 [12] . To identify patients with coccidioidomycosis receiving voriconazole or posaconazole, we searched the institution's mandatory reports sent to the Arizona Department of Health Services for all patients with coccidioidomycosis from 1 January 2006 through 1 August 2010. For all identified patients, we manually searched the electronic prescription pad for voriconazole or posaconazole and then reviewed medical records. Abstracted data included demographic and clinical information; underlying medical conditions, including use of immunosuppressive medications; results of laboratory studies, including serum and cerebrospinal fluid serology; microbiology and pathology findings; radiographic studies; details of antifungal treatments; and outcomes. Patients were excluded if they had ,1 month of follow-up after initiation of voriconazole or posaconazole therapy. The Mayo Clinic Institutional Review Board approved this study.
Responses to therapy were tabulated using a modified Mycosis Study Group (MSG) score [13] . Retrospectively, we assigned each patient an MSG score on initiation of voriconazole or posaconazole and again at the end of the follow-up period or last episode of care. The MSG score is a composite score, comprising the sum of points assigned by the following characteristics: (1) a clinical symptoms score, with 1 point given for each symptom listed; (2) a radiographic imaging scoring system, with points assigned for the size of the abnormality, the presence of satellite lesions, associated adenopathy, and changes in size or presence of infiltrates; and (3) serology points, with a complement fixation titer of 1:2 assigned 1 point, 1:4 assigned 2 points, 1:8 assigned 3 points, and so forth. All coccidioidal serologic tests were performed at Mayo Clinic laboratories.
Responses to treatment were assigned to 1 of 3 categories: improved, stable, or unresponsive. An improved outcome was defined as one of the following: (1) $50% improvement (as reflected by a lower numerical score) in the MSG score; (2) the unequivocal documentation of clinical improvement as recorded on the progress note of the medical provider; or (3) a 25%-49% decrease in the MSG score and a physician's impression of improvement as recorded on the progress note. A stable outcome was defined as an unchanged MSG score or one that declined by ,25% by the end of follow-up. An unresponsive outcome was defined as one of the following: (1) the MSG score increased (reflecting progressive infection); (2) progress notes reported relapsed or progressing infection; (3) patients stopped therapy because of intolerance or cost.
Owing to differences in practice or documentation, not all patients had a complete record of clinical symptoms and serologic and radiographic results for initial or final visits. When data were missing in either the initial or final visit, the MSG score was modified, consisting of the sum of points present at both the initial and the final visits (for example, if clinical data were missing at a final visit, then the compared scores included only serologic or radiographic components). Simple descriptive statistics were used to summarize the data. Continuous variables were reported as medians and means; categorical variables, as percentages. Fisher's exact test was used to compare proportions.
RESULTS
Thirty-five patients met inclusion criteria. Six patients received both voriconazole and posaconazole sequentially, and 2 of them met criteria for inclusion in both groups. Therefore, 21 voriconazole recipients and 16 posaconazole recipients are described ( Supplementary Tables 1 and 2 ; online only).
Voriconazole
Thirty patients were initially identified as recipients of voriconazole; 9 were excluded because they had ,1 month of medication treatment, resulting in 21 evaluable patients (Table 1;  Table S1 ; online only). Table 2 Fourteen of 21 patients (67%) showed improvement, on the basis of a $50% decline in MSG score (n 5 8), an unequivocal statement on progress notes (n 5 1), or the combination of 25%-49% improvement in score accompanied by a clinician's statement of improvement (n 5 5). The median treatment duration for the 8 patients with a $50% MSG decline was 15 months (range, 3-36 months), and the median treatment duration for the 5 patients with a 25%-49% MSG decline was 3 months (range, 2-6 months). Five patients with stable outcomes were treated for a median of 4 months (range, 1-10 months). Two patients were unresponsive, 1 on the basis of medication intolerance.
Among the 5 patients whose outcome was stable, 3 had data missing, and initial or follow-up scores were not calculable. For each of these 3, progress notes did not provide enough information to conclude that improvement had occurred at the end of follow-up. One patient returned to long-term fluconazole treatment, and 2 switched to posaconazole. One patient with a stable outcome had a 25% reduction in MSG score (directly attributable to a 1-dilution decline in serologic titer) and a therapeutic voriconazole serum level, but infection persisted at the site of the articular elbow coccidioidal infection after 9 months of voriconazole treatment.
One patient with disseminated coccidioidomycosis had serologic and clinical improvement in the first 2 years after starting salvage therapy with voriconazole, with MSG scores decreasing from 5 at the beginning to 2 at the end of voriconazole treatment. However, her infection relapsed despite continued treatment, prompting a change to posaconazole. Another patient with a therapeutic voriconazole serum level had a 25% reduction in MSG score after 2 months of treatment, which was attributed to a single-dilution decline in serologic titer, but the medication was discontinued because of intolerance, and the patient was classified as unresponsive.
Serum voriconazole levels were measured in 5 patients. Among these, 3 patients were unresponsive, although 2 had therapeutic levels. Two of the 5 patients showed improvement, 1 of whom had a therapeutic level. Voriconazole was generally well tolerated. One of 21 patients required discontinuation for photopsia and a photosensitive skin reaction.
Posaconazole
Eighteen patients who received posaconazole were initially identified. Two were excluded because of insufficient records; thus, 16 patients met study criteria (Table 1; Supplementary  Table 2 , online only). Table 2 summarizes the outcome of posaconazole treatment. All 16 patients received initial treatment with fluconazole (daily dosage range, 400-800 mg, either orally or intravenously; duration range, 1-60 months) before initiation of posaconazole. Seven patients had also previously received voriconazole, itraconazole, or L-AMB (Table 1) .
The median duration of posaconazole therapy was 17 months. Fifteen patients (94%) received .3 months of therapy. Thirteen of the 16 were treated with 400 mg twice daily, but 1 patient received up to 600 mg twice daily. There were no recorded events of noncompliance or intermittent use.
Twelve of the 16 posaconazole recipients showed improvement, on the basis of either a $50% decline in MSG score (n 5 8) or the combination of a 25%-49% MSG decline accompanied by clinicians' statements of improvement (n 5 4). The median treatment duration for the 8 patients with a $50% decline was 22 months (range, 8-24 months), and the median duration for the 4 with a 25%-49% MSG decline was 7.5 months (range, 5-24 months). One patient had a stable outcome after 5 months. Three patients were unresponsive, because of either premature cessation of medication (n 5 1; medication intolerance) or relapsed infection after initial improvement (n 5 2). Serum posaconazole levels were determined in 2 patients. A measurable but subtherapeutic level was noted in a patient who was unresponsive (despite adjustment of dose). A therapeutic level was identified in a patient who showed improvement.
DISCUSSION
The first effective antifungal agent for coccidioidomycosis was amphotericin B deoxycholate, but its use was complicated by frequent and severe toxicity; currently, its use is reserved for patients with fulminant or rapidly progressing coccidioidomycosis [14, 15] . Fluconazole and itraconazole were subsequently developed, studied, and deemed effective and well-tolerated alternatives to amphotericin B; these agents have now been used for decades to treat patients with coccidioidomycosis who require antifungal therapy [14, 16] . However, these agents are occasionally inadequate for completely controlling chronic pulmonary or disseminated coccidioidomycosis. In the current study, fluconazole was consistently the first-line treatment. Fluconazole has a wide therapeutic-toxic ratio [17] , and daily doses of #1200 milligrams are generally tolerable. We noted that the daily dose of fluconazole before a switch to another medication was typically 400 mg but up to 1000 mg in some patients. We speculate that the availability of other medication options may have led to switching to an alternate agent at lower doses of fluconazole than previously observed. Additionally, a few patients were intolerant of or refractory to L-AMB or itraconazole.
Voriconazole and posaconazole are newer triazoles with broader antifungal activity than either fluconazole or itraconazole [18] . Both medications disrupt the synthesis of ergosterol, a key component of the fungal cell membrane. Both have been used successfully as salvage treatment for refractory coccidioidomycosis, either alone or as a component of a multidrug regimen [19, 20] , as documented in case reports [5-7, 10, 21] and small case series [4, 9] (Table 3) . Additionally, 2 small, openlabel prospective studies demonstrated the utility of posaconazole in refractory chronic and nonmeningeal disseminated coccidioidomycosis (improvement in 11 of 15 patients [8] ) and in primary treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis (improvement in 17 of 20 patients [11] ).
Voriconazole is available in parenteral and oral formulations, with excellent oral bioavailability independent of gastric acidity [22, 23] . When voriconazole is taken with high-fat meals, however, its absorption is modestly decreased. Voriconazole has a wide distribution into tissues and its penetration of the central nervous system (CNS) resembles that of fluconazole [24] . There is substantial inter-and intrasubject variability in serum concentrations [18, [25] [26] [27] , whether the drug is administered intravenously or orally. Most of this pharmacokinetic variability is attributed to differences in the ability of the CYP2C19 enzyme to metabolize voriconazole [18] , and polymorphisms in the DNA encoding this enzyme are common. Voriconazole is an inhibitor of CYP2C8/9, CYP2C19, and CYP3A4 enzymes, all of which can be a source of multiple drug interactions [22] . Voriconazole serum concentrations correlate with antifungal efficacy (including for Aspergillus and Candida species [18, 26] ) and toxicity (including neurotoxicity, photopsia, and elevated liver enzymes [18, 26] ). Photopsia, noted in #30% patients, is self-limited but was disturbing enough for 1 patient in the current study to discontinue the medication.
Posaconazole is currently available only in a liquid oral formulation; its absorption may be gastric acid dependent [18] but is improved by ingestion of a fatty meal [28] . Although posaconazole has a long half-life, it is optimally administered multiple times daily because of its saturable absorption [23] . Pharmacokinetic studies have identified marked interpatient variability, possibly because posaconazole must be administered with food [23] . Although highly protein bound, posaconazole has a large volume of distribution [28] . Posaconazole may have low or variable penetration into the CNS [29, 30] , although some clinical efficacy has been demonstrated against CNS fungal infections (primarily Cryptococcus species) [21] . Serum posaconazole levels correlate with efficacy in noncoccidioidal infections (Aspergillus and Candida species [23] ).
Therapeutic drug monitoring is increasingly recognized as an important assessment with the use of these medications because of interpatient variability in serum levels and the correlation of therapeutic levels with treatment response [18, 22, 23, 26] . In our cohort, serum levels were measured in 7 of the 35 patients, 4 of whom were not responding adequately to therapy. With very limited data, we did not find a direct correlation between therapeutic levels and success, nor between subtherapeutic levels and failure. However, a larger cohort with serial levels would be more likely to substantiate such relationships for patients undergoing treatment of coccidioidomycosis.
The current study examined the use of voriconazole and/or posaconazole under ''real-life'' clinical conditions for patients with coccidioidomycosis who were intolerant of first-line medications or whose disease was refractory. On the basis of improved MSG scores and the favorable impressions of health care providers, we found improvement in 14 of 21 voriconazole recipients (67%) and in 12 of 16 posaconazole recipients (75%). The differences in the percentage of improvement between these 2 groups cannot be used for the purpose of comparison; such a comparison would require a prospective randomized trial.
Of the 2 patients included in both treatment groups, neither had substantial improvement with either medication. Both patients were immunosuppressed and had disseminated infection. One required an increased dosage of posaconazole after documentation of a subtherapeutic serum level. It is unknown whether there was a resistant organism, poor compliance, problematic dosing, unrecognized drug interaction, or some other issue influencing the course of treatment.
One patient from each treatment group had coccidioidal meningitis; both showed improvement. Voriconazole achieves CNS concentrations comparable to those of fluconazole [24] , whereas the posaconazole CNS penetration may be low or variable [29, 30] . Including the present report, a total of 6 cases of successful voriconazole treatment of coccidioidal meningitis have been published ( [4, 5, 7] ; present report), whereas treatment was unsuccessful in 1 published case [4] . Posaconazole was reported as successful or partially successful in the treatment of 24 of 39 patients with refractory (primarily cryptococcal) fungal meningitis [21] . One of the 39 had coccidioidal meningitis and achieved a partial response with posaconazole. Our cohort includes another patient with coccidioidal meningitis who showed improvement with posaconazole. However, we also identified a patient whose posaconazole failure was manifested by newly emergent coccidioidal meningitis. If a decision is made to use posaconazole for meningitis, careful monitoring of therapeutic serum levels and cerebrospinal fluid treatment response should be considered.
In both the voriconazole and posaconazole groups, patients with better responses were treated for longer durations than were patients with less robust improvement, although some overlap occurred in treatment durations. The 6 patients (on either medication) who had a stable clinical response were also treated for a shorter time, and longer follow-up may bear out further improvement. One author reported that, of 6 patients with coccidioidomycosis who eventually responded to voriconazole, only 2 had a good response by 2 months of treatment [4] ; other reports have indicated success after several months of either voriconazole or posaconazole treatment [5] [6] [7] [8] [9] .
In patients receiving either voriconazole or posaconazole, immunosuppression did not seem to influence the clinical outcome: 18 of 23 nonimmunosuppressed patients (78%) showed improvement, compared with 8 of 12 immunosuppressed patients (67%) (P 5 0.6). Similarly, outcomes were no different for patients with pulmonary infection than for those with disseminated infection (Table 2) ; 15 of 20 patients (75%) had improved outcomes, compared with 11 of 15 patients (73%), respectively (P . 0.99). In both observations, the small sample size may have missed a trend that bears further scrutiny. In previous reports on voriconazole or posaconazole (Table 3) , 15 of 20 patients (75%) with disseminated infection experienced improvement [4, [6] [7] [8] [9] [10] .
Voriconazole, the first of the 2 agents available for clinical use, was selected as the first salvage agent for 21 of our 35 patients. Beyond simple availability, we did not identify an individual factor or a consistent theme that drove the decision making about the selection of voriconazole or posaconazole as the first salvage agent. Voriconazole use is associated with concerns of variable bioavailability, multiple potential drug interactions, and toxic effects that include photopsia and phototoxic skin reactions; CNS penetration may be a reason to choose this agent over posaconazole. Posaconazole is limited to an oral liquid preparation, which patients may not favor, but the drug has fewer potential medication interactions and toxic effects; experience in CNS infections is more limited. In addition, insurance coverage might sometimes be the deciding factor. Currently, no comparative data exist on the use of these agents for salvage treatment of coccidioidomycosis.
This study had several limitations. It was a retrospective case series, and the application of points to arrive at MSG scores was difficult because of variable documentation of symptoms and timing of laboratory studies. Multiple health care providers were involved in the medical care of these patients. The costs for voriconazole and posaconazole were high, and a few patients encountered concerns because of limits to their insurance coverage. Because the follow-up for some patients was relatively short and there was no medication washout period, we cannot exclude the possibility of clinical improvement that occurred as the result of the first treatment rather than the second. Therapeutic medication levels were not uniformly determined.
In conclusion, we found both voriconazole and posaconazole to be excellent but not infallible options for salvage treatment of patients with refractory coccidioidomycosis. Most patients tolerated these treatments well and achieved improvement and control of their coccidioidal infections. A prospective clinical trial may identify situations in which one of these agents is preferable to the other.
